Business Context and Reporting Period
Company: Prana Biotechnology Limited (ASX: PBT)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: June 2013 (Specifically June 28, 2013)
Context: The filing discloses the issuance of unlisted options under the company's Employee Incentive Scheme and Consulting Agreements. The document serves as a new issue announcement and application for quotation of additional securities with the Australian Securities Exchange (ASX).
Key Financial Metrics and Capital Structure
Revenue, Profit, and Cash Flow: The filing text does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. This document is a capital structure disclosure, not a financial results report.
Capital Structure Details:
- Ordinary Shares on Issue: 381,610,426
- New Securities Issued: 1,683,791 Unlisted Options
- Exercise Price: AUD$0.37
- Expiry Date: June 25, 2018
- Consideration: Nil cash consideration
- Total Unlisted Options (All Classes): 36,536,516
Material Changes
The primary material change reported is the issuance of 1,683,791 new unlisted options. These securities were issued under an exception in ASX Listing Rule 7.2 (Rule 7.2 exception) rather than under the standard 15% placement capacity (Rule 7.1) or the additional 10% capacity for eligible entities (Rule 7.1A).
Placement Capacity Status (as of filing):
- Remaining Rule 7.1 Capacity: 47,876,582 securities
- Remaining Rule 7.1A Capacity: 9,476,012 securities
Guidance, Outlook, and Risks
Management Commentary: The issuance was executed pursuant to the Employee Incentive Scheme and Consulting Agreements. Security holder approval for the scheme was previously obtained on December 12, 2012.
Risks and Contingencies: The filing includes standard warranties to the ASX that the issue complies with the law, is not for an illegal purpose, and that no "excluded information" exists that requires disclosure. The company warrants that the securities rank equally with existing ordinary shares upon exercise.
Unusual Items: None reported beyond the standard option grant.
Investor Verification Checklist
- Verify the total number of outstanding options across all classes (36.5 million) to assess potential future dilution.
- Confirm the exercise price of the new tranche (AUD$0.37) relative to the current market price to determine if the options are in-the-money.
- Review the remaining placement capacity under Rules 7.1 and 7.1A to understand the company's ability to raise capital without shareholder approval in the near term.
- Check subsequent filings for financial performance data, as this 6-K contains no revenue or earnings information.